Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies
Prenatal Diagnosis · 2023-06 · 43 (7) · 814-828
DOI: 10.1002/pd.6357 ↗At a glance
Journal article in Prenatal Diagnosis, published online on 2023-05-16. Written by Lisa Hui and 8 co-authors. Institution: Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia. Major MEDLINE topics: Prenatal Diagnosis, Chromosome Disorders. Cited 109 times so far (Crossref); 116 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHGRI NIH HHS, NIH HHS.
Abstract (original language)
Key points What is already known about this topic? In 2015, the International Society for Prenatal Diagnosis (ISPD) published its first position statement on the use of non‐invasive prenatal testing (NIPT) to screen for aneuploidy. Widespread uptake across the globe and subsequent published research has shed new light on test performance and implementation issues. What does this study add? This new position statement replaces the 2015 statement with updated information on the current technologies, clinical experience, and implementation practices. As an international organization, ISPD recognizes that there are important population‐specific considerations in the organization of prenatal screening and diagnosis. These opinions are designed to apply to high income settings where prenatal screening for aneuploidy is an established part of antenatal care. This position statement is not a clinical practice guideline but represents the consensus opinion of the current ISPD Board based on the current state of knowledge and clinical practice.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.
- Reproductive Epidemiology Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Department of Perinatal Medicine, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
- Department of Obstetrics and Gynaecology, Northern Health, Epping, Victoria, Australia.
- Illumina ANZ, Sydney, New South Wales, Australia.
- Genetics Clinic, Hospital Angeles Lomas, Estado de Mexico, Mexico.
ORCID profiles: Lisa Hui, Mark D Pertile, Rebecca Reimers, Luming Sun, Joris Vermeesch, Neeta L Vora, Lyn S Chitty
Funding
- NHGRI NIH HHS
- NIH HHS
Cite
APA
Hui, L., Ellis, K., Mayen, D., Pertile, M. D., Reimers, R., Sun, L., Vermeesch, J., Vora, N. L., & Chitty, L. S. (2023). Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies. Prenatal Diagnosis, 43(7), 814-828. https://doi.org/10.1002/pd.6357
Vancouver
Hui L, Ellis K, Mayen D, Pertile MD, Reimers R, Sun L, et al. Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies. Prenatal Diagnosis. 2023;43(7):814-828. doi:10.1002/pd.6357
BibTeX
@article{Hui2023,
author = {Hui, Lisa and Ellis, Katie and Mayen, Dora and Pertile, Mark D and Reimers, Rebecca and Sun, Luming and Vermeesch, Joris and Vora, Neeta L and Chitty, Lyn S},
title = {Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies},
journal = {Prenatal Diagnosis},
year = {2023},
volume = {43},
number = {7},
pages = {814--828},
doi = {10.1002/pd.6357}
}
EUVIMED